Pre-clinically, this combination is particularly efficacious against CT26 colon carcinoma cells (108–110), which interestingly harbor a Cdkn2a deletion and expresses functional RB (143, 144), likely rendering it highly sensitive to the tumor-intrinsic immunomodulatory effects of CDK4/6 inhibition. This evidence concerns the gene RB1 and neoplasm.